Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to...
Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN...
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated...
ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United...
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0001 | -0.00454545454546 | 2.2 | 2.37 | 2.0588 | 919471 | 2.24241685 | CS |
| 4 | 0.8199 | 59.4130434783 | 1.38 | 2.595 | 1.26 | 1264843 | 2.04243501 | CS |
| 12 | -3.1601 | -58.9570895522 | 5.36 | 6.98 | 0.87 | 2092797 | 1.99668786 | CS |
| 26 | -6.9801 | -76.0359477124 | 9.18 | 9.25 | 0.87 | 1063777 | 2.54858486 | CS |
| 52 | -5.2401 | -70.4314516129 | 7.44 | 12.8499 | 0.87 | 1104265 | 5.56153033 | CS |
| 156 | -24.4001 | -91.7296992481 | 26.6 | 42.4 | 0.87 | 1886172 | 12.89964335 | CS |
| 260 | -18.6001 | -89.4235576923 | 20.8 | 85.2 | 0.87 | 1944010 | 22.51599587 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
